Lexeo Therapeutics, Inc. LXEO
We take great care to ensure that the data presented and summarized in this overview for Lexeo Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in LXEO
Top Purchases
Top Sells
About LXEO
Insider Transactions at LXEO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2025
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,193
+0.98%
|
$4,386
$2.64 P/Share
|
|
Aug 29
2025
|
Louis Edward Tamayo Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+50.0%
|
-
|
|
Aug 18
2025
|
Jose Manuel Otero Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
2,848
-4.5%
|
$11,392
$4.67 P/Share
|
|
Aug 18
2025
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,735
-1.23%
|
$10,940
$4.67 P/Share
|
|
Aug 18
2025
|
Eric Adler Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
608
-0.9%
|
$2,432
$4.67 P/Share
|
|
Aug 18
2025
|
Jenny Robertson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
542
-0.86%
|
$2,168
$4.67 P/Share
|
|
Aug 18
2025
|
Tai Sandi See Chief Development Officer |
SELL
Open market or private sale
|
Direct |
382
-0.64%
|
$1,528
$4.67 P/Share
|
|
May 16
2025
|
Tai Sandi See Chief Development Officer |
SELL
Open market or private sale
|
Direct |
367
-0.62%
|
$734
$2.77 P/Share
|
|
May 16
2025
|
Jenny Robertson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
521
-0.82%
|
$1,042
$2.77 P/Share
|
|
May 16
2025
|
Eric Adler Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
585
-0.86%
|
$1,170
$2.77 P/Share
|
|
May 16
2025
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,074
-0.48%
|
$2,148
$2.77 P/Share
|
|
Mar 14
2025
|
Tai Sandi See Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+8.76%
|
$11,440
$2.61 P/Share
|
|
Mar 14
2025
|
Jenny Robertson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+8.25%
|
$11,440
$2.61 P/Share
|
|
Mar 14
2025
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,720
+8.3%
|
$11,440
$2.61 P/Share
|
|
Mar 14
2025
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,128
+0.95%
|
$4,256
$2.61 P/Share
|
|
Feb 19
2025
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,326
-1.93%
|
$17,304
$4.41 P/Share
|
|
Feb 19
2025
|
Jenny Robertson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,101
-3.5%
|
$8,404
$4.41 P/Share
|
|
Feb 19
2025
|
Eric Adler Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,359
-3.34%
|
$9,436
$4.41 P/Share
|
|
Feb 19
2025
|
Tai Sandi See Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,486
-2.68%
|
$5,944
$4.41 P/Share
|
|
Jan 17
2025
|
Kyle Rasbach Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,875
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
381K
Shares
From
9
Insiders
| Open market or private purchase | 15K shares |
|---|---|
| Grant, award, or other acquisition | 356K shares |
| Exercise of conversion of derivative security | 10K shares |
Sell / Disposition
29.9K
Shares
From
5
Insiders
| Open market or private sale | 29.9K shares |
|---|